Clinical Trial

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.
Protocol Amendment History 1 change
notable Sponsor changed: Wave Life Sciences Ltd. -> Wave Life Sciences USA, Inc. 2026-05-31
Trial Details
NCT Number NCT06405633
Lead Sponsor Wave Life Sciences Ltd.
Conditions Alpha-1 Antitrypsin Deficiency
Enrollment 24 participants
Start Date 2024-07-19
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-14